IgGenix Completes $10 Million Series A Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--IgGenix, Inc, today announced it completed a $10 million Series A financing. The financing was led by Khosla Ventures with participation from Parker Ventures and will be used to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies and other severe allergic conditions. Founded in 2019 by Stephen Quake, D. Phil; Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.; Derek Croote, Ph.D., and Bruce Hironaka, IgGen